Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005055993 - PHARMACEUTICAL PREPARATION CONTAINING GABAPENTIN

Publication Number WO/2005/055993
Publication Date 23.06.2005
International Application No. PCT/EP2004/053233
International Filing Date 02.12.2004
IPC
A61K 9/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
A61K 9/20 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61P 25/08 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
CPC
A61K 31/195
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
A61K 9/1641
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1629Organic macromolecular compounds
1641obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
A61K 9/2077
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2072characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
A61P 25/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
A61P 25/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
10for petit-mal
A61P 25/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
12for grand-mal
Applicants
  • ZAMBON GROUP S.P.A. [IT]/[IT] (AllExceptUS)
  • RAMPOLDI, Luca [IT]/[IT] (UsOnly)
  • GRASSANO, Alessandro [IT]/[IT] (UsOnly)
Inventors
  • RAMPOLDI, Luca
  • GRASSANO, Alessandro
Agents
  • LONGONI, Alessandra
Priority Data
MI2003A00239909.12.2003IT
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PHARMACEUTICAL PREPARATION CONTAINING GABAPENTIN
(FR) PREPARATION PHARMACEUTIQUE COMPRENANT DE LA GABAPENTINE
Abstract
(EN) A gabapentin granulate obtained by granulating gabapentin with PEG having a melting point comprised between 50 and 80°C and pharmaceutical compositions containing it, are described.
(FR) L'invention concerne un granulé de gabapentine obtenu par granulation de la gabapentine avec PEG possédant un point de fusion compris entre 50 et 80 °C et des compostions pharmaceutiques renfermant celui-ci.
Latest bibliographic data on file with the International Bureau